SRPT vs WLYB · rev $1.13B vs P/E 15, $2.26B cap
Sarepta Therapeutics Inc (SRPT) versus John Wiley & Sons B (WLYB) — a side-by-side from cached financials, not a winner call.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
John Wiley & Sons B (WLYB) is a publishing company listed on NYSE.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
WLYB does not have a complete income-statement cache yet.
SRPT currently screens at market cap $2.34B. WLYB currently screens at market cap $2.26B and trailing P/E 15.4.
Not investment advice. Open the SRPT and WLYB stock pages for the full models.
Not investment advice.